Fujirebio, a leading innovator in in-vitro diagnostics, has announced a strategic collaboration with Stanford Medicine to advance research and innovation in infectious disease testing. The partnership aims to accelerate the adoption of ultrasensitive immunoassays that incorporate single-molecule counting technology developed by Fujirebio's Silicon Valley wholly-owned subsidiary, Fluxus, Inc.
The collaboration focuses on enhancing test sensitivity to better inform treatment decisions in clinical settings while accelerating studies toward therapeutics and preventive strategies against infectious disease threats worldwide.
Technology and Innovation Focus
The partnership centers on Fluxus's ultrasensitive detection systems, which utilize single-molecule counting technology to achieve greater diagnostic sensitivity than conventional methods. This enhanced sensitivity capability is designed to improve clinical decision-making and support research into new therapeutic approaches for infectious diseases.
"This collaboration represents a significant step forward in our mission to improve public health globally, by combining Fujirebio's global IVD expertise and Fluxus' ultrasensitive detection systems with Stanford's world-renowned research," said Dr. Peter Wagner, President and CEO of Fluxus, Inc.
Academic Partnership Structure
The collaboration involves Stanford's Clinical Virology Laboratory under the direction of Professor Benjamin Pinsky and the Stanford Clinical Microbiology Laboratory under the direction of Professor Niaz Banaei. This partnership brings together Stanford's infectious disease research expertise with Fujirebio's diagnostic technology capabilities.
"By working with the Stanford Clinical Virology Laboratory under the direction of Professor Benjamin Pinsky and the Stanford Clinical Microbiology Laboratory under the direction of Professor Niaz Banaei, we are bringing together world-class scientific expertise, cutting-edge technology, and global health insights," said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc.
Global Health Impact
The collaboration addresses what company leadership describes as one of the greatest global health challenges of the current era. The partnership aims to create diagnostic solutions that can contribute to a more resilient global health infrastructure through improved infectious disease detection and monitoring capabilities.
Fujirebio, a member of H.U. Group Holdings Inc., operates as an R&D-driven company focused on developing new IVD testing technologies and unique biomarkers with high clinical value. The company maintains global operations across Japan, Asia, Europe, and the United States, focusing on delivering high-quality diagnostic solutions through industry partnerships.
Fluxus specializes in optofluidic technologies and develops ultrasensitive detection systems and assay solutions designed to advance the diagnosis, monitoring, and treatment of diseases.
